Forecast

There is no analyst data available for this company.

News Go to news feed

Vector signs letter of intent with LyoGenesis Plus and Wynn for IV adapter products

Vector, LyoGenesis Plus and Wynn signed a letter of intent to develop and manufacture adapter products for infusion bags and vials, focused on active ingredients on the FDA “Short List.” Production is scheduled to start in three to four months; Wynn estimates an initial market potential of more than USD 20 million annually and projects up to USD 64 million in annual revenue within five years. Vector will manage customer and sales relationships and receive about 75% of revenues; LyoGenesis Plus will act as a contract manufacturer and receive around 25% plus cost reimbursement. LyoGenesis Plus is an affiliate of Vector. » More on de.investing.com

Financials

In the last quarter, VECTOR ACQ. CL.A DL-,0001 had revenue of €205.09M and net profit of -€43.16M

(EUR)	Jun 2026	YoY
Revenue	205.09M	67.29%
Gross profit	74.11M	88.29%
Net profit	-43.16M	23.40%
EBITDA	-50.39M	13.47%

Fundamentals

Metric	Value
Market capitalization	€4.77B
Number of shares	477.65M
52-week high/low	€10.25 - €9.59
Dividends	No
Beta	0.00
P/E ratio	-89.00
PEG ratio	-0.56
P/B ratio	2.05
P/S ratio	7.19

Company profile

Vector Acquisition Corp. konzentriert sich auf die Durchführung von Fusionen, Aktientausch, Übernahme von Vermögenswerten, Aktienkauf, Umstrukturierung oder ähnlichen Unternehmenszusammenschlüssen mit einem oder mehreren Unternehmen. Das Unternehmen wurde im Jahr 2020 gegründet und hat seinen Sitz in San Francisco, Kalifornien.